Cancer of Kidney Clinical Trial
Official title:
A Single Arm Phase 1 Study of Microwave Coagulation Using 2450-MHz Antennae and CO2 Cooling in Partial Nephrectomy for T1 Renal Tumors
Verified date | January 2018 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Partial nephrectomy (kidney removal) is a standard therapy for clinical T1 renal (kidney)
tumors. The goals of surgery are to accurately remove the tumor with no cancer cells at the
edge of the remaining tissue, to limit blood loss, and preserve kidney function. The most
common technique is to clamp the blood supply to the entire kidney during removal and to
surgically repair the tumor bed with suture and agents to stop bleeding. This stops the blood
supply to the entire kidney including the healthy tissue, which can cause damage to the
remaining tissue due to a shortage of oxygen if left clamped too long.
This study uses a microwave pre-coagulation technique using the Certus 140™ to facilitate a
bloodless area near the tumor for accurate tumor removal and repair, while avoiding clamping
the blood supply, but its effect on the function of kidney adjacent to tumor is unknown. If
adequate stoppage of bleeding is achieved using the Certus 140™ with minimal heat spreading
to the remaining tissue, clamping and a shortage of oxygen can be avoided.
The hypothesis is that microwave pre-coagulation is a safe method for providing the stoppage
of bleeding during partial kidney removal.
Status | Terminated |
Enrollment | 2 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patient must have a solitary, polar, clinical T1 renal mass 2. Patient must have adequate kidney function as measured by eGFR (estimated glomerular filtration rate) greater than or equal to 50 calculated from a standard care serum creatinine performed within 30 days prior to the partial nephrectomy operation. 3. Women of child-bearing potential must have negative serum or urine pregnancy test 4. Patient must be able to give written informed consent 5. Patient must be 18 years or older 6. No blood-thinning medications, including anti-inflammatory medications, herbs and supplements for at least 1 week prior to surgery Exclusion Criteria: 1. T stage greater than clinical T1 2. Tumor extends beyond kidney into major veins, perinephric tissues, or adrenal gland 3. Prior surgery or radiation therapy to the region of interest 4. Patient has a single functioning kidney 5. Patient has an uncorrectable coagulopathy 6. Patient is not a surgical candidate due to underlying cardiac or other serious comorbid condition |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To Assess the Effectiveness of Microwave Pre-coagulation Using the Certus 140™ System for Partial Nephrectomy on Renal Function Using the Estimated Glomerular Filtration Rate. | We will be measuring the change in renal function as quantified by pre- and post-surgical estimated Glomerular Filtration Rate. Change = (6 week score - Baseline score) | 30 days prior to surgery (Baseline) and 6 weeks post surgery | |
Secondary | Blood Loss | To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring blood loss. We will calculate the mean, median, standard deviation, and range of values for blood loss. | During the operation | |
Secondary | Operative Time | To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring operative time. We will calculate the mean, median, standard deviation, and range of values for operative time. | During the operation | |
Secondary | Clamp Time | To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring clamp time. We will calculate the mean, median, standard deviation, and range of values for clamp time. | During the operation | |
Secondary | Change in Renal Function | To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring the change in renal function by nuclear scan and creatinine clearance. We will calculate the mean, median, standard deviation, and range of values for change in renal function by nuclear scan and creatinine clearance. | Within 30 days prior to operation and 6 weeks post operation | |
Secondary | Change in Functional Renal Volume | To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring the change in functional renal volume as measured by MRI. We will calculate the mean, median, standard deviation, and range of values for change in functional renal volume as measured by MRI. | Within 30 days prior to operation and 6 weeks post-operation | |
Secondary | Tumor Margin | The percentage of subjects with tumor positive margins will be reported. Tissue pathology will occur during the operation and a final tissue pathology will be performed 6 weeks after the operation. | During the operation and 6 weeks post-operation | |
Secondary | Complication Rates | Complication rates will be estimated using the methods of Kaplan and Meier. | During the operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Recruiting |
NCT02121730 -
Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Not yet recruiting |
NCT05241561 -
Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
|
Phase 2 | |
Completed |
NCT00199888 -
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
|
Phase 1 | |
Completed |
NCT05363072 -
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
|
||
Withdrawn |
NCT04127318 -
Low-moderate Intensity Pedaling During Immunotherapy Administration
|
N/A | |
Recruiting |
NCT03452774 -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
|
||
Recruiting |
NCT05732857 -
Valveless Trocar Versus Standard Trocar in Robot-assisted Complex Partial Nephrectomy
|
N/A | |
Recruiting |
NCT03133286 -
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
|
||
Completed |
NCT02145559 -
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
|
Phase 1 |